# Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss

> **NCT00221312** · — · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 48 (actual)

## Conditions studied

- Perimenopausal Bone Loss

## Interventions

- **DRUG:** Fosamax

## Key facts

- **NCT ID:** NCT00221312
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2008-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00221312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00221312, "Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00221312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*